Cigna (NYSE:CI) had its price target reduced by Morgan Stanley from $241.00 to $207.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. They currently have an overweight rating on the health services provider’s stock.
CI has been the topic of a number of other reports. Citigroup raised shares of Atara Biotherapeutics from a sell rating to a neutral rating and lifted their target price for the stock from $23.00 to $24.00 in a research note on Monday, June 3rd. Barclays set a $24.00 target price on shares of Tenet Healthcare and gave the stock a hold rating in a research note on Wednesday, April 17th. Cantor Fitzgerald reaffirmed a buy rating and set a $75.00 target price on shares of Emergent Biosolutions in a research note on Sunday, April 21st. UBS Group set a $36.00 price target on shares of Halliburton and gave the company a buy rating in a research report on Tuesday, April 23rd. Finally, ValuEngine cut shares of Ultrapar Participacoes from a sell rating to a strong sell rating in a research report on Thursday, April 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $217.40.
Shares of CI stock opened at $177.03 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.89. The stock’s 50-day moving average price is $159.39. Cigna has a 12 month low of $141.95 and a 12 month high of $226.60. The stock has a market capitalization of $67.38 billion, a P/E ratio of 12.45, a PEG ratio of 0.88 and a beta of 0.71.
Cigna (NYSE:CI) last issued its earnings results on Thursday, May 2nd. The health services provider reported $3.90 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.16. Cigna had a net margin of 4.11% and a return on equity of 14.23%. The company had revenue of $33.43 billion for the quarter, compared to the consensus estimate of $32.79 billion. During the same period in the previous year, the firm earned $4.11 earnings per share. Cigna’s quarterly revenue was up 192.9% compared to the same quarter last year. As a group, analysts anticipate that Cigna will post 16.55 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in CI. Clarfeld Financial Advisors LLC acquired a new position in shares of Cigna in the fourth quarter valued at approximately $25,000. Claybrook Capital LLC acquired a new position in Cigna during the 4th quarter worth approximately $34,000. Lowe Wealth Advisors LLC acquired a new position in Cigna during the 1st quarter worth approximately $34,000. Truvestments Capital LLC acquired a new position in Cigna during the 1st quarter worth approximately $37,000. Finally, Lavaca Capital LLC acquired a new position in Cigna during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 88.08% of the company’s stock.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
See Also: What can cause a stock to outperform?
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.